Goldman Sachs Upgrades Myriad Genetics (MYGN) to Neutral
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.06 +0.99%
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Join SI Premium – FREE
Goldman Sachs upgraded Myriad Genetics (NASDAQ: MYGN) from Sell to Neutral with a price target of $21.
The firm said the BRCAnalysis franchise does not face acute near-term risk and capital deployment has become more progressive.
For more ratings news on Myriad Genetics click here and for the rating history of Myriad Genetics click here.
Shares of Myriad Genetics closed at $18.43 yesterday.
The firm said the BRCAnalysis franchise does not face acute near-term risk and capital deployment has become more progressive.
For more ratings news on Myriad Genetics click here and for the rating history of Myriad Genetics click here.
Shares of Myriad Genetics closed at $18.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
